#Typestatus plus 11.3 trial#
The power of the trial was 80%, with a potential type I error of 0.05. The experimental ORR was compared with an estimated ORR of 60% based on historical data, verified by a randomized control group (FOLFOXIRI). The experimental arm (modified FOLFOXIRI plus panitumumab) was considered active if the ORR was ≥ 75%. The primary end point was objective response rate (ORR) according to RECIST (version 1.1). This trial investigated the addition of panitumumab to triplet chemotherapy with fluorouracil/folinic acid, oxaliplatin, and irinotecan (FOLFOXIRI) in a two-to-one randomized, controlled, open-label, phase II trial in patients with untreated RAS wild-type (WT) metastatic colorectal cancer. The safety profile of the combination of cetuximab and FOLFOXIRI was acceptable and promising anti-tumor activity was demonstrated, supporting further study in patients with RAS wild-type mCRC. The ORR was 89% (95% confidence interval 52–100%).Conclusion No dose-limiting toxicities occurred in any of the enrolled patients. The most frequent grade 3/4 adverse events were neutropenia (44%), fatigue (11%), paronychia (22%), and acneiform rash (11%). The MTD was not reached at dose level 2 and the RP2D was 150 mg/m2 irinotecan. Secondary endpoints included safety, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).ResultsNine patients were enrolled. The primary endpoint was to determine the maximum-tolerated dose (MTD) and the recommended phase-2 dose (RP2D). The dose level of irinotecan was escalated starting at dose level 1 in a 3 + 3 manner. Patients with previously untreated RAS wild-type mCRC received weekly cetuximab (400 mg/m2 at week 1 and subsequently 250 mg/m2) plus FOLFOXIRI that consisted of irinotecan (100, 120, and 150 mg/m2 defined as dose levels 0, 1, and 2), followed by oxaliplatin 85 mg/m2 and l-leucovorin 200 mg/m2 and then 5-fluorouracil 2400 mg/m2. This phase Ib study assessed the safety of FOLFOXIRI plus cetuximab in Japanese patients with RAS wild-type mCRC.Methods We hope you enjoy it.The triplet-agent (5-fluorouracil/leucovorin, oxaliplatin, and irinotecan FOLFOXIRI) combined with an anti-epidermal growth factor receptor antibody as a first-line treatment of metastatic colorectal cancer (mCRC) has shown promising results in Western trials. We’ve put a ton of work into TypeStatus Plus. Now, you can always see when someone is composing a message to you. You also will get notifications for when someone starts typing, so that when you’re away from your phone, all of your TypeStatus Plus notifications will still be there. If you don’t have any unread messages, TypeStatus Plus will remove it from your status bar, leaving it clutter free. From the TypeStatus Plus settings, you can configure any app and the badge count for said app will be in your status bar at all times. In addition, you can keep track of your unread messages.
There has never been a way to access the messaging from the typing indicator with such ease. If someone is typing for a while, and you don’t really know what’s going on, you can always click the typing indicator in your status bar to open up the messages app to your conversation. When you’re talking to multiple people at once, this will really come in handy. When you’re in the conversation list, a typing indicator will conveniently be added to the given conversation. In your Messages app, you can always see who is typing. TypeStatus Plus deeply integrates with the Apple Watch, leaving you with a sleek interface to enjoy.
#Typestatus plus 11.3 Bluetooth#
TypeStatus Plus supports the Apple Watch and Bluetooth Low Energy devices, such as the Pebble smartwatch. With TypeStatus Plus, you will never be left without typing notifications.
With this addition, it is unlikely there will be an app TypeStatus Plus doesn’t support. TypeStatus Plus has an API allowing developers to make “providers” to support any given app. Whether this is WhatsApp, Facebook Messenger, Telegram, or even the default iOS Messages app, TypeStatus Plus supports all of these and more.īut, it does not end there. TypeStatus Plus can help you see who currently typing a message to you no matter what app you use. The extension to the legendary tweak TypeStatus.
0 kommentar(er)
